HRP-Deruxtecan (Dxd) (1:1) Conjugate

Deruxtecan is an exatecan (Exa) derivative appended with a cleavable peptide linker. It is a very potent inhibitor of topoisomerase I and an anticancer agent. Deruxtecan is used to prepare antibody-drug conjugates (ADCs), such as trastuzumab Deruxtecan (T-DXd, also known as Enhertu®, Daiichi Sankyo), targeting HER2. Deruxtecan is approved in HER2-expressing breast (BC) and gastric (GC) cancers. This HRP-Deruxtecan conjugate is designed with similar linker chemistry as ADCs and PDCs prepared by our customer using our Antibody Deruxtecan Conjugation Kit (Cat#: CM11431) and our Protein Deruxtecan Conjugation Kit (Cat#: CM11432). This conjugate is synthesized for our customer's use in horseradish peroxidase (HRP) based assays. A long flexible PEG linker is also incorporated in the conjugate to retain HRP activity and Deruxtecan binding. The final conjugate is HPLC-purified to obtain 1:1 Deruxtecan-labeled HRP and is lyophilized from PBS buffer containing sugar-based stabilizer for easy shipping and storage.

The product is sold as 1 vial of 0.5 mg (Cat# CM53215-0.5MG) or 4 vials of 0.5 mg (Cat# CM53215-2MG). For bulk orders beyond this range, please contact us for a quote.

Key Features
• Lyophilized powder is ready for usage after reconstitution with water, no need for external buffer.
• HPLC-purified single-labeled conjugate, 1:1 HRP-Deruxtecan
• Retained HRP activity, 200-300 units/mg protein (1 unit is the amount of enzyme that will form 1.0 mg purpurogallin from pyrogallol in 20s at pH 6.0 at 20°C).
• A long flexible PEG linker incorporated to retain the HRP activity and Deruxtecan binding.

Please contact us at for specific academic pricing.